The company Amgen has published the ninth edition of its 'Biosimilar Trends Report', referring to the year 2022 and to North American healthcare. This study offers detailed information on aspects such as the evolution of the penetration of biosimilars according to their different active ingredients or the savings for the health system in the chapter on pharmaceutical provision.